viewEden Research plc

Eden Research expects to report 48% jump in revenue, modest operating profit after year of “pleasing growth”

The AIM-listed company said its 2018 revenue is expected to be in the region of £2.8mln, up from £1.9m in 2017, with a loss before tax of approximately £1.0mln, versus a £0.8mln loss in 2017

Eden research added that it expects to report an operating profit of around £0.02mln, against an operating loss of £0.6mln in 2017

Eden Research PLC (LON:EDEN) expects to report full-year 2018 revenue of 48% and a modest operating profit after a year of “pleasing growth” for the biopesticide products developer.

In a trading update for the year ended 31 December 2018, the AIM-listed company said its revenue for the year is expected to be in the region of £2.8mln, up from £1.9m in 2017, with a loss before tax of approximately £1.0mln, versus a £0.8mln loss in 2017.

WATCH: Eden Research positioned for growth after 'pleasing' performance in 2018

The firm added that it expects to report an operating profit, excluding share-based payment charges, exceptional royalties refund and amortisation, of around £0.02mln, against an operating loss of £0.6mln in 2017.

Eden Research said the majority of revenue growth came from product sales which doubled in 2018 to around £1.6mln, up from £0.8mln in 2017, with the balance the revenue being made up of upfront, milestone and other payments and royalties.

The group said its cash position remains strong with cash at the 2018 year-end of around £2.5mln, against £3.7mln in 2017.

Sean Smith, Eden Research’s chief executive officer of said: “We are pleased with the overall performance of the business in 2018 and believe that we have established an excellent platform from which we can continue to grow both in 2019 and, importantly, the medium and long term."

READ: Eden Research grape fungicide set for push into US and other regions as commercial partner picks up distribution option

He added: "2018 showed continued growth in the sale of Mevalone in southern Europe despite low disease pressure attributed to another hot, dry summer.

“We are encouraged by the doubling of Mevalone sales during the year as this reflects the increasing acceptance of Mevalone in the market, the optimised product positioning initiated by our partners and its adoption and continued use by growers.”

Smith continued: “The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. 

“Whilst it is early in the development of these formulations, initial results have been encouraging.

Quick facts: Eden Research plc

Price: 7.975 GBX

Market: AIM
Market Cap: £16.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Eden Research plc named herein, including the promotion by the Company of Eden Research plc in any Content on the Site, the Company receives...



Eden Research gets 'emergency use' green light for Mevalone in France

Eden Research PLC's (LON:EDEN) Sean Smith tells Proactive London's Andrew Scott their fungicide, Mevalone, has been granted 120-day emergency use authorisation in France for the treatment of storage diseases on apples. Smith says the emergency use approval represents the first...

on 30/7/19

2 min read